Skip to content

Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health

Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01053481
Enrollment
25
Registered
2010-01-21
Start date
2010-03-31
Completion date
2011-10-31
Last updated
2013-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteopenia

Brief summary

The purpose of this study is to determine whether increasing levels of serum 25(OH)Vitamin D as achieved by oral supplementation higher than the current recommendations are associated with a less negative bone calcium balance in post-menopausal Swiss women.

Detailed description

In a substudy - not related to the vitamin D intervention - spot and 24 h urine samples are compared with regard to the assessment of iodine status in Swiss post-menopausal women. In an short subsequent study using five of the subjects who participated in the original trial, the effect of a 40 d-exercise program (rebounding on a trampoline) on Ca-41 excretion will be observed.

Interventions

DIETARY_SUPPLEMENTvitamin D

Vitamin D supplement

BEHAVIORALexercise program (rebounding on a trampoline)

40 days at 30 min/d

Sponsors

DSM Nutritional Products, Inc.
CollaboratorINDUSTRY
Swiss Federal Institute of Technology
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
55 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* apparently healthy women, at least 5 years post-menopausal * BMI 18-30 * no HRT * no regular intake of Ca or vit D supplements * wiling and able to give written informed consent and to understand, participate and comply with study requirements * non-smokers * no long travels (\>3 wk) planned within study period

Exclusion criteria

* diseases that predispose to osteoporosis * history of fragility fractures * currently on a weight reduction program * excessive physical activity * diseases influencing calcium metabolism (thyroid, parathyroid, adrenal disorders etc.) * regular intake of medication affecting calcium metabolism * osteoporosis (T-score below -2.5) * history of psychological illness likely to interfere with the subject's ability to understand the requirements of the study * participation in concurrent studies

Design outcomes

Primary

MeasureTime frame
urinary Ca-41/Ca-40 ratioMarch 2010 to January 2011

Secondary

MeasureTime frameDescription
biomarkers of bone metabolismMarch 2010 to January 2011
urinary iodineAugust 2009 to December 2010Comparison of spot and 24 h urine samples for the assessment of iodine status (substudy, not related to vitamin D intervention)

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026